ReleaseWire

Rectal Cancer - Pipeline Review, H2 2014

Sentinext Therapeutics Sdn Bhd - Product Pipeline Review - 2014

Global Markets Direct's, 'Pherecydes Pharma SA - Product Pipeline Review - 2014', provides an overview of the Pherecydes Pharma SA's pharmaceutical research and development focus.

Global Markets Direct's, 'Chronic Pain - Pipeline Review, H2 2014', provides an overview of the Chronic Pain's therapeutic pipeline.

Global Markets Direct's, 'Immune Targeting Systems (ITS) Ltd. - Product Pipeline Review - 2014', provides an overview of the Immune Targeting Systems (ITS) Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Seasonal Influenza - Pipeline Review, H2 2014', provides an overview of the Seasonal Influenza's therapeutic pipeline.

Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

TxCell SA - Product Pipeline Review - 2014

Global Markets Direct's, 'Malignant Pleural Mesothelioma - Pipeline Review, H2 2014', provides an overview of the Malignant Pleural Mesothelioma's therapeutic pipeline.

Global Markets Direct's, 'Intarcia Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Intarcia Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2014', provides an overview of the Duchenne Muscular Dystrophy's therapeutic pipeline.

Global Markets Direct's, 'Nuron Biotech, Inc. - Product Pipeline Review - 2014', provides an overview of the Nuron Biotech, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Syntrix Biosystems, Inc. - Product Pipeline Review - 2014', provides an overview of the Syntrix Biosystems, Inc.'s pharmaceutical research and development focus.

Sound Pharmaceuticals, Inc. - Product Pipeline Review - 2014

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" “the company”) today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible.

Global Markets Direct's, 'Boston Biomedical, Inc. - Product Pipeline Review - 2014', provides an overview of the Boston Biomedical, Inc.'s pharmaceutical research and development focus.

Orchid Chemicals & Pharmaceuticals Ltd - Product Pipeline Review - 2014

BioCrea GmbH - Product Pipeline Review - 2014

Zydus Cadila Healthcare Limited - Product Pipeline Review - 2014

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H2 2014', provides an overview of the Down Syndrome's therapeutic pipeline.

Yuhan Corporation - Product Pipeline Review - 2014

Dermolab Pharma, a Montreal based pharmaceutical manufacturing company announces its capacity to produce phytotherapeutic products. In an effort to expand their production capacities and offer the most diverse services possible to their clients, company officials claim their facilities have the capacity to produce, among many other types of pharmaceuticals, plant extract juices with PSN. These natural health products are commercially popular among an environmentally-conscious clientele that are wary of chemical substances and prefer natural solutions.

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014

Vulvovaginal Candidiasis - Pipeline Review, H2 2014

Forest Laboratories, Inc. - Product Pipeline Review - 2014